Canadian Pacific Kansas City Limited Common Shares vs Heron Therapeutics Inc — how do they compare? Canadian Pacific Kansas City Limited Common Shares trades at $83.86 (market cap $73.98B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Canadian Pacific Kansas City Limited Common Shares is far larger — about 999.2× Heron Therapeutics Inc's market cap, and Canadian Pacific Kansas City Limited Common Shares pays a 0.9% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CP | HRTX | |
|---|---|---|
Market Cap | $73.98B | $74.04M |
Volume | 1,669,828 | 3,668,095 |
Sector | Industrials | Health |
52-Week High | $96.69 | $1.49 |
52-Week Low | $68.88 | $0.27 |
Enterprise Value | $91.36B | $180.78M |
Dividend Yield | 0.9% | — |
Typical Hold Time | — | 35 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Canadian Pacific Kansas City operates a freight railway connecting Canada, the United States, and Mexico. The company was formed through the combination of Canadian Pacific and Kansas City Southern.
Read more on CP →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →